FEATURED

Four FDA Approvals in One Week • Novartis Drops $3B • The Obesity War Just Got a New Front

Mar 23, 2026

•

11 min read

Four FDA Approvals in One Week • Novartis Drops $3B • The Obesity War Just Got a New Front

Wegovy HD, Imcivree, Icotyde, and Lynavoy all cleared. Novartis grabs a breast cancer asset. And retatrutide put the metabolic field on notice.

BioMed Nexus

THE LATEST

Mar 20, 2026

•

9 min read

Rhythm Wins HO Approval | Lilly's Triple Agonist Crushes Ph3 | The GLP-1 Arms Race

Imcivree lands its fourth indication, retatrutide delivers 36.6 lbs of weight loss in diabetes, and Lilly builds a metabolic monopoly.

Mar 19, 2026

•

10 min read

J&J Cracks the Oral IL-23 Code • Gossamer Cuts 48% • Rhythm's Moment Is Tomorrow

First oral targeted psoriasis pill gets FDA nod, another PAH contender craters, and Imcivree's HO decision lands in less than 24 hours.

Mar 18, 2026

•

10 min read

Bicycle Shelves Padcev Challenger • Aldeyra's 3rd CRL • Jensen Huang's $1T Flex

Rhythm's PDUFA lands Friday, Lilly's obesity pill decision looms, and GTC puts pharma AI under the microscope.

Pharma’s GPU Arms Race Accelerates: Roche vs. Lilly at GTC

ACIP meets Wednesday, Rhythm’s PDUFA lands Friday, and China clears the first commercial BCI.

Lilly Flags GLP-1 Impurity • Hims Exits Compounding • Sana Durability

Sana validates the T1D cure thesis at 14 months, ACIP meets Wednesday, and Rhythm's PDUFA lands Friday.

Lilly's Compounding Crackdown • Ultragenyx Hits Ph3 • Novo's Asset Slide

A new tirzepatide-B12 impurity escalates the GLP-1 compounding war as Pfizer winds down its biotech incubator.

BridgeBio’s LGMD Breakthrough • Stryker Cyberattack • Vima Adds $40M

FORTIFY Phase 3 data positions BBP-418 as the first LGMD therapy while Evotec cuts 800 jobs and CAR-T competition intensifies.

FDA Sets “Trial-Free” Precedent for Ultra-Rare Disease • BioNTech Founders Pivot • Hims Lands Ozempic

Leucovorin approved using literature evidence alone as BioNTech shares drop and GLP-1 telehealth tensions ease.

Japan Approves First iPS Therapies • Xenon’s Record Epilepsy Data • FDA Eases Biosimilar Path

Azetukalner posts the strongest pivotal epilepsy efficacy ever as Vertex advances its kidney disease filing.

Servier Buys Day One for $2.5B • CBER Chief Prasad to Exit • Lonza’s $3B CDMO Pivot

MDA conference opens as MiniMed’s weak IPO and Zealand’s petrelintide data reshape the obesity race.

J&J’s 55-Day FDA Approval • CVS & Google Launch AI Health Platform • TrumpRx Stalls

Tec-Dara combo sets a new myeloma benchmark as Atavistik closes a $160M raise.

SUBSCRIBE TO OUR NEWSLETTER

Stay on the Cutting Edge of Biotech, MedTech, and Pharma.